Budi Baktijasa Dharmadjati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Budi Baktijasa Dharmadjati has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ricardo Adrian Nugraha
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia, Indonesia
8 shared publications - Yudi Her Oktaviono
Universitas Airlangga
8 shared publications - Achmad Lefi
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
4 shared publications - Agus Subagjo
Division of Echocardiography, Department of Cardiology and Vascular Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia, Indonesia
4 shared publications - Budi Susetyo Pikir
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia
4 shared publications - Mochamad Yusuf Alsagaff
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia
4 shared publications
Latest Publications
- Open Access
- 4 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1716
RURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Due to an inconsistent result about predictors of 30-day outcomes regarding scoring systems for the first episode of acute myocardial infarction, the objective of this study is to develop novel scoring systems to predict 30-day mortality among patients with a first episode of acute myocardial infarction who underwent primary percutaneous coronary intervention. Methods: This retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction who underwent primary percutaneous coronary intervention between 2021 and 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling and collected 1714 patients, of which 1535 patients were included. Our primary outcomes included 30-day mortality. Results: The analysis included 1535 patients: 926 in the derivation set and 609 in the validation set. In our study, the 30-day mortality rate was 20.7%. Multivariate logistic regression analysis was used to build prediction models in the derivation group and then validated in the validation cohort. The area under the ROC curve of the RURUS SURYAWAN score to predict 30-day mortality was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set, with 94.6% sensitivity and 97.3% specificity (p < 0.001). Conclusions: After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictors of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- 4 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1716
Open AccessRURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Due to an inconsistent result about predictors of 30-day outcomes regarding scoring systems for the first episode of acute myocardial infarction, the objective of this study is to develop novel scoring systems to predict 30-day mortality among patients with a first episode of acute myocardial infarction who underwent primary percutaneous coronary intervention. Methods: This retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction who underwent primary percutaneous coronary intervention between 2021 and 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling and collected 1714 patients, of which 1535 patients were included. Our primary outcomes included 30-day mortality. Results: The analysis included 1535 patients: 926 in the derivation set and 609 in the validation set. In our study, the 30-day mortality rate was 20.7%. Multivariate logistic regression analysis was used to build prediction models in the derivation group and then validated in the validation cohort. The area under the ROC curve of the RURUS SURYAWAN score to predict 30-day mortality was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set, with 94.6% sensitivity and 97.3% specificity (p < 0.001). Conclusions: After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictors of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- Open Access
- 26 December 2024
- Published by MDPI AG in Preprints.org
RURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Given an inconsistent result about predictors of 30-day outcomes regarding scoring system for first episode of acute myocardial infarction, the objective of this study is to develop novel scoring system to predict 30-day mortality among patients with first episode of acute myocardial infarction underwent primary percutaneous coronary intervention. Methodology. Retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction underwent primary percutaneous coronary intervention, between 2021 to 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling, collected 1714 patients, in which 1535 patients were included.. Primary outcomes were 30-day mortality. Results. The analysis included 1535 patients: derivation set 926 and validation set 609. In our study, the 30-day mortality was 20.7%. Multivariate logistic regression analysis was used to build prediction models in derivation group, and then validated in validation cohort. Discrimination, calibration and clinical usefulness of the predicting model were assessed using the C-index, calibration plot and decision curve analysis. After pairwise comparison, the best performing model was chosen to build a nomogram according to the regression coefficients. The AUROC was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set. Conclusion. After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictor of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- 26 December 2024
- Published by MDPI AG in Preprints.org
Open AccessRURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Given an inconsistent result about predictors of 30-day outcomes regarding scoring system for first episode of acute myocardial infarction, the objective of this study is to develop novel scoring system to predict 30-day mortality among patients with first episode of acute myocardial infarction underwent primary percutaneous coronary intervention. Methodology. Retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction underwent primary percutaneous coronary intervention, between 2021 to 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling, collected 1714 patients, in which 1535 patients were included.. Primary outcomes were 30-day mortality. Results. The analysis included 1535 patients: derivation set 926 and validation set 609. In our study, the 30-day mortality was 20.7%. Multivariate logistic regression analysis was used to build prediction models in derivation group, and then validated in validation cohort. Discrimination, calibration and clinical usefulness of the predicting model were assessed using the C-index, calibration plot and decision curve analysis. After pairwise comparison, the best performing model was chosen to build a nomogram according to the regression coefficients. The AUROC was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set. Conclusion. After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictor of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- Open Access
- 11 June 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 851
Reversine enhances the conversion of dedifferentiated fat cells into mature cardiomyocytes
Background There is an essential need for cardiomyocyte regeneration among patients with heart failure. Transplantation of dedifferentiated fat (DFAT) cells may lead to an improvement of cardiomyocyte regeneration among heart failure patients. We believe that DFAT cells are promising candidate cell sources for cardiac regeneration. However, the pathway underlying how DFAT cells of the adipose lineage differentiate into mature cardiomyocytes isn’t fully understood. Methods We conducted an experimental laboratory study on isolated DFAT cells from adipose tissue of healthy adults. Then, we treated cells with different concentrations of reversine (10, 20 and 40 nM), and performed RNA extraction and cDNA synthesis. Next, we used a ceiling culture method based on the buoyancy properties of mature lipid-filled adipocytes. Stemness expression (Octamer-binding transcription factor 4 [Oct4], brachyury, Fetal liver kinase 1 [Flk-1]) was quantified by reverse transcription-quantitative (RT-q)PCR, while cardiomyocyte expression (Transcription factor GATA-4 [GATA4] and cardiac troponin T [cTnT]) was quantified by immunocytochemistry. Results ANOVA with Tukey’s post-hoc found that 10 nM reversine increased greater Flk-1 expression compared to the control group (MD: 5.037 + 0.998; p < 0.001), but there were no significant changes among Oct4 (MD: 0.013 + 1.244; p = 0.99) and brachyury expression (MD: 0.157 + 0.084; p = 0.252). Kruskal-Wallis revealed that the expression of GATA4 (1.65 [0.41-1.98] to 0.015 [0.007-0.034]; p =0.017) reduced significantly from day 7 until day 21 and cTnT (5.07 [6.62-8.91] to 8.22 [6.81-9.40]; p= 0.001) increased significantly from day 7 until day 21. Conclusions Reversine could increase the expression of Flk-1, but it was unable to stimulate the expression of Oct4 and brachyury related to cell stemness. An optimal concentration of 10 nM reversine may have the greatest effect on enhancing the differentiation of DFAT cells into mature cardiomyocytes, as indicated by higher cTnT expression between cells.
- 11 June 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 851
Open AccessReversine enhances the conversion of dedifferentiated fat cells into mature cardiomyocytes
Background There is an essential need for cardiomyocyte regeneration among patients with heart failure. Transplantation of dedifferentiated fat (DFAT) cells may lead to an improvement of cardiomyocyte regeneration among heart failure patients. We believe that DFAT cells are promising candidate cell sources for cardiac regeneration. However, the pathway underlying how DFAT cells of the adipose lineage differentiate into mature cardiomyocytes isn’t fully understood. Methods We conducted an experimental laboratory study on isolated DFAT cells from adipose tissue of healthy adults. Then, we treated cells with different concentrations of reversine (10, 20 and 40 nM), and performed RNA extraction and cDNA synthesis. Next, we used a ceiling culture method based on the buoyancy properties of mature lipid-filled adipocytes. Stemness expression (Octamer-binding transcription factor 4 [Oct4], brachyury, Fetal liver kinase 1 [Flk-1]) was quantified by reverse transcription-quantitative (RT-q)PCR, while cardiomyocyte expression (Transcription factor GATA-4 [GATA4] and cardiac troponin T [cTnT]) was quantified by immunocytochemistry. Results ANOVA with Tukey’s post-hoc found that 10 nM reversine increased greater Flk-1 expression compared to the control group (MD: 5.037 + 0.998; p < 0.001), but there were no significant changes among Oct4 (MD: 0.013 + 1.244; p = 0.99) and brachyury expression (MD: 0.157 + 0.084; p = 0.252). Kruskal-Wallis revealed that the expression of GATA4 (1.65 [0.41-1.98] to 0.015 [0.007-0.034]; p =0.017) reduced significantly from day 7 until day 21 and cTnT (5.07 [6.62-8.91] to 8.22 [6.81-9.40]; p= 0.001) increased significantly from day 7 until day 21. Conclusions Reversine could increase the expression of Flk-1, but it was unable to stimulate the expression of Oct4 and brachyury related to cell stemness. An optimal concentration of 10 nM reversine may have the greatest effect on enhancing the differentiation of DFAT cells into mature cardiomyocytes, as indicated by higher cTnT expression between cells.
- Open Access
- 22 March 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 851
Effects of different concentrations of reversine to enhance conversion of dedifferentiated fat cells into mature cardiomyocytes
Background There is an essential need for cardiomyocyte regeneration among patients with heart failure. Transplantation of dedifferentiated fat (DFAT) cells may lead to an improvement of cardiomyocyte regeneration among heart failure patients. We believe that DFAT cells are promising candidate cell sources for cardiac regeneration. However, the pathway underlying how DFAT cells of the adipose lineage differentiate into mature cardiomyocytes isn’t fully understood. Methods We conducted an experimental laboratory study on isolated DFAT cells from adipose tissue of healthy adults. Then, we treated cells with different concentrations of reversine (10, 20 and 40 nM), and performed RNA extraction and cDNA synthesis. Next, we used a ceiling culture method based on the buoyancy properties of mature lipid-filled adipocytes. Stemness expression (Octamer-binding transcription factor 4 [Oct4], brachyury, Fetal liver kinase 1 [Flk-1]) was quantified by reverse transcription-quantitative (RT-q)PCR, while cardiomyocyte expression (Transcription factor GATA-4 [GATA4] and cardiac troponin T [cTnT]) was quantified by immunocytochemistry. Results ANOVA with Tukey’s post-hoc found that 10 nM reversine increased greater Flk-1 expression compared to the control group (MD: 5.037 + 0.998; p < 0.001), but there were no significant changes among Oct4 (MD: 0.013 + 1.244; p = 0.99) and brachyury expression (MD: 0.157 + 0.084; p = 0.252). Kruskal-Wallis revealed that the expression of GATA4 (1.65 [0.41-1.98] to 0.015 [0.007-0.034]; p =0.017) reduced significantly from day 7 until day 21 and cTnT (5.07 [6.62-8.91] to 8.22 [6.81-9.40]; p= 0.001) increased significantly from day 7 until day 21. Conclusions Reversine could increase the expression of Flk-1, but it was unable to stimulate the expression of Oct4 and brachyury related to stem cell-ness. An optimal concentration of 10 nM reversine may have the greatest effect on enhancing the differentiation of DFAT cells into mature cardiomyocytes, as indicated by higher cTnT expression between cells.
- 22 March 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 851
Open AccessEffects of different concentrations of reversine to enhance conversion of dedifferentiated fat cells into mature cardiomyocytes
Background There is an essential need for cardiomyocyte regeneration among patients with heart failure. Transplantation of dedifferentiated fat (DFAT) cells may lead to an improvement of cardiomyocyte regeneration among heart failure patients. We believe that DFAT cells are promising candidate cell sources for cardiac regeneration. However, the pathway underlying how DFAT cells of the adipose lineage differentiate into mature cardiomyocytes isn’t fully understood. Methods We conducted an experimental laboratory study on isolated DFAT cells from adipose tissue of healthy adults. Then, we treated cells with different concentrations of reversine (10, 20 and 40 nM), and performed RNA extraction and cDNA synthesis. Next, we used a ceiling culture method based on the buoyancy properties of mature lipid-filled adipocytes. Stemness expression (Octamer-binding transcription factor 4 [Oct4], brachyury, Fetal liver kinase 1 [Flk-1]) was quantified by reverse transcription-quantitative (RT-q)PCR, while cardiomyocyte expression (Transcription factor GATA-4 [GATA4] and cardiac troponin T [cTnT]) was quantified by immunocytochemistry. Results ANOVA with Tukey’s post-hoc found that 10 nM reversine increased greater Flk-1 expression compared to the control group (MD: 5.037 + 0.998; p < 0.001), but there were no significant changes among Oct4 (MD: 0.013 + 1.244; p = 0.99) and brachyury expression (MD: 0.157 + 0.084; p = 0.252). Kruskal-Wallis revealed that the expression of GATA4 (1.65 [0.41-1.98] to 0.015 [0.007-0.034]; p =0.017) reduced significantly from day 7 until day 21 and cTnT (5.07 [6.62-8.91] to 8.22 [6.81-9.40]; p= 0.001) increased significantly from day 7 until day 21. Conclusions Reversine could increase the expression of Flk-1, but it was unable to stimulate the expression of Oct4 and brachyury related to stem cell-ness. An optimal concentration of 10 nM reversine may have the greatest effect on enhancing the differentiation of DFAT cells into mature cardiomyocytes, as indicated by higher cTnT expression between cells.
- Open Access
- 8 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 352
Quantification of hs-Troponin Levels and Global Longitudinal Strain among Critical COVID-19 Patients with Myocardial Involvement
Background. Myocardial involvement among critically ill patients with coronavirus disease 2019 (COVID-19) often has worse outcomes. An imbalance in the oxygen supply causes the excessive release of pro-inflammatory cytokines, which results in increased ventilation requirements and the risk of death in COVID-19 patients. Purpose. We evaluated the association between the hs-troponin I levels and global longitudinal strain (GLS) as evidence of myocardial involvement among critical COVID-19 patients. Methods. We conducted a prospective cohort study from 1 February to 31 July 2021 at RSUD Dr. Soetomo, Surabaya, as a COVID-19 referral center. Of the 65 critical COVID-19 patients included, 41 (63.1%) were men, with a median age (interquartile range) of 51.0 years (20.0–75.0). Subjects were recruited based on WHO criteria for severe COVID-19, and myocardial involvement in the form of myocarditis was assessed using CDC criteria. Subjects were examined using echocardiography to measure the GLS, and blood samples were taken to measure the hs-troponin. Subjects were then followed for their need for mechanical ventilation and in-hospital mortality. Results. Severe COVID-19 patients with cardiac injury were associated with an increased need for intubation (78.5%) and an increased incidence of myocarditis (50.8%). There was a relationship between the use of intubation and the risk of death in patients (66.7% vs. 33.3%, p-value < 0.001). Decreased GLS and increased hs-troponin were associated with increased myocarditis (p values < 0.001 and 0.004, respectively). Decreased GLS was associated with a higher need for mechanical ventilation (12.17 + 4.79 vs. 15.65 + 4.90, p-value = 0.02) and higher mortality (11.36 + 4.64 vs. 14.74 + 4.82; p-value = 0.005). Elevated hs-troponin was associated with a higher need for mechanical ventilation (25.33% vs. 3.56%, p-value = 0.002) and higher mortality (34.57% vs. 5.76%, p-value = 0.002). Conclusions. Critically ill COVID-19 patients with myocardial involvement and elevated cardiac troponin levels are associated with a higher need for mechanical ventilation and higher mortality.
- 8 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 352
Open AccessQuantification of hs-Troponin Levels and Global Longitudinal Strain among Critical COVID-19 Patients with Myocardial Involvement
Background. Myocardial involvement among critically ill patients with coronavirus disease 2019 (COVID-19) often has worse outcomes. An imbalance in the oxygen supply causes the excessive release of pro-inflammatory cytokines, which results in increased ventilation requirements and the risk of death in COVID-19 patients. Purpose. We evaluated the association between the hs-troponin I levels and global longitudinal strain (GLS) as evidence of myocardial involvement among critical COVID-19 patients. Methods. We conducted a prospective cohort study from 1 February to 31 July 2021 at RSUD Dr. Soetomo, Surabaya, as a COVID-19 referral center. Of the 65 critical COVID-19 patients included, 41 (63.1%) were men, with a median age (interquartile range) of 51.0 years (20.0–75.0). Subjects were recruited based on WHO criteria for severe COVID-19, and myocardial involvement in the form of myocarditis was assessed using CDC criteria. Subjects were examined using echocardiography to measure the GLS, and blood samples were taken to measure the hs-troponin. Subjects were then followed for their need for mechanical ventilation and in-hospital mortality. Results. Severe COVID-19 patients with cardiac injury were associated with an increased need for intubation (78.5%) and an increased incidence of myocarditis (50.8%). There was a relationship between the use of intubation and the risk of death in patients (66.7% vs. 33.3%, p-value < 0.001). Decreased GLS and increased hs-troponin were associated with increased myocarditis (p values < 0.001 and 0.004, respectively). Decreased GLS was associated with a higher need for mechanical ventilation (12.17 + 4.79 vs. 15.65 + 4.90, p-value = 0.02) and higher mortality (11.36 + 4.64 vs. 14.74 + 4.82; p-value = 0.005). Elevated hs-troponin was associated with a higher need for mechanical ventilation (25.33% vs. 3.56%, p-value = 0.002) and higher mortality (34.57% vs. 5.76%, p-value = 0.002). Conclusions. Critically ill COVID-19 patients with myocardial involvement and elevated cardiac troponin levels are associated with a higher need for mechanical ventilation and higher mortality.
- Open Access
- 9 November 2023
- Published by MDPI AG in Preprints.org
Different Inhibition Mechanism of Atorvastatin, Olmesartan, and Resveratrol in Experimental Pathological Myofibroblast Heart Valve Model
Background. Recent studies revealed that differentiation of valvular interstitial cell into myofibroblasts played an important role in pathological valve remodeling in rheumatic valvular disease. Objective. To investigate effects of atorvastatin, olmesartan, and resveratrol on Transforming Growth Factor β1-induced fibrosis. Methods. Valvular interstitial cell was isolated from 12-weeks male New Zealand rabbit (Oryctolagus cuniculus). Culture cells was divided into 4 groups, control group, group I (0.5 mg/mL Atorvastatin), group II (100 nmol/L Olmesartan), group III (50 μM/L Resveratrol) and group IV (combinations). All group were exposed to 100 nM Transforming Growth Factor β1 for 24 hours. Results. Immunochemical staining demonstrated that cells were completely differentiated into myofibroblasts with mean expression of α-smooth muscle actin 24522.64±4566.994. Atorvastatin, olmesartan, resveratrol, and its combination significantly reduced α-smooth muscle actin expression (6823±1735.3, 6942.7±2455.9, 14176.2±3343.3, 5051.8±1612.2 respectively (p<0.001). Conclusion. Our data showed atorvastatin, olmesartan, resveratrol, and its combination significantly reduce Transforming Growth Factor β1-induced valvular fibrosis.
- 9 November 2023
- Published by MDPI AG in Preprints.org
Open AccessDifferent Inhibition Mechanism of Atorvastatin, Olmesartan, and Resveratrol in Experimental Pathological Myofibroblast Heart Valve Model
Background. Recent studies revealed that differentiation of valvular interstitial cell into myofibroblasts played an important role in pathological valve remodeling in rheumatic valvular disease. Objective. To investigate effects of atorvastatin, olmesartan, and resveratrol on Transforming Growth Factor β1-induced fibrosis. Methods. Valvular interstitial cell was isolated from 12-weeks male New Zealand rabbit (Oryctolagus cuniculus). Culture cells was divided into 4 groups, control group, group I (0.5 mg/mL Atorvastatin), group II (100 nmol/L Olmesartan), group III (50 μM/L Resveratrol) and group IV (combinations). All group were exposed to 100 nM Transforming Growth Factor β1 for 24 hours. Results. Immunochemical staining demonstrated that cells were completely differentiated into myofibroblasts with mean expression of α-smooth muscle actin 24522.64±4566.994. Atorvastatin, olmesartan, resveratrol, and its combination significantly reduced α-smooth muscle actin expression (6823±1735.3, 6942.7±2455.9, 14176.2±3343.3, 5051.8±1612.2 respectively (p<0.001). Conclusion. Our data showed atorvastatin, olmesartan, resveratrol, and its combination significantly reduce Transforming Growth Factor β1-induced valvular fibrosis.
- Open Access
- 24 October 2023
- Published by MDPI AG in Preprints.org
Quantification of hs-Troponin Level and Global Longitudinal Strain among Critical COVID-19 Patients with Myocardial Involvement
Myocardial involvement among critical patients with coronavirus disease 2019 (COVID-19) has a worse outcome. The occurrence of an imbalance in oxygen supply results in the release of pro-inflammatory cytokines which leads to increased ventilation support requirement and increase risk of mortality. Our aim was to evaluate the association between hs-Troponin I level and global longitudinal strain as evidence of myocardial involvement among critical COVID-19 patients. Methods. We performed prospective cohort study from February 1st – July 31st, 2021 at Dr. Soetomo General Hospital, Surabaya as referral center for COVID-19 care. Of the 65 critical COVID-19 included, 41 (63.1%) were men, with a median (interquartile range) age of 51.0 years (20.0-75.0).Subjects were recruited according to WHO criteria for severe COVID-19 and CDC criteria for myocarditis. All subjects recruited were examined using echocardiography to measure global longitudinal strain (GLS) and blood samples were taken to measure hs-Troponin. Subjects were then followed to assess their needs for mechanical ventilation and in-hospital mortality. Severe COVID-19 subjects with cardiac injury were associated with an increased need for intubation (78.5%) and an increased incidence of myocarditis (50.8%). There was an association between the use of intubation and the risk of mortality in patients (66.7% vs. 33.3%, p-value <0.001). Both reduced GLS and increased hs-troponin are associated with increased myocarditis (p-value <0.001 and 0.004 respectively). Reduced GLS is associated with higher mechanical ventilation needs (12.17 + 4.79 vs.15.65 + 4.90, p-value 0.02) and a higher mortality rate (11.36 + 4.64 vs. 14.74 + 4.82; p-value 0.005). Increased hs-troponin is associated with higher mechanical ventilation needs (25.33% vs. 3.56%, p-value 0.002) and a higher mortality rate (34.57% vs. 5.76%, p-value 0.002). Compared with contemporary controls, critical COVID-19 patients with myocardial involvement and elevated cardiac troponin level are associated with higher mechanical ventilation needs and a higher mortality rate.
- 24 October 2023
- Published by MDPI AG in Preprints.org
Open AccessQuantification of hs-Troponin Level and Global Longitudinal Strain among Critical COVID-19 Patients with Myocardial Involvement
Myocardial involvement among critical patients with coronavirus disease 2019 (COVID-19) has a worse outcome. The occurrence of an imbalance in oxygen supply results in the release of pro-inflammatory cytokines which leads to increased ventilation support requirement and increase risk of mortality. Our aim was to evaluate the association between hs-Troponin I level and global longitudinal strain as evidence of myocardial involvement among critical COVID-19 patients. Methods. We performed prospective cohort study from February 1st – July 31st, 2021 at Dr. Soetomo General Hospital, Surabaya as referral center for COVID-19 care. Of the 65 critical COVID-19 included, 41 (63.1%) were men, with a median (interquartile range) age of 51.0 years (20.0-75.0).Subjects were recruited according to WHO criteria for severe COVID-19 and CDC criteria for myocarditis. All subjects recruited were examined using echocardiography to measure global longitudinal strain (GLS) and blood samples were taken to measure hs-Troponin. Subjects were then followed to assess their needs for mechanical ventilation and in-hospital mortality. Severe COVID-19 subjects with cardiac injury were associated with an increased need for intubation (78.5%) and an increased incidence of myocarditis (50.8%). There was an association between the use of intubation and the risk of mortality in patients (66.7% vs. 33.3%, p-value <0.001). Both reduced GLS and increased hs-troponin are associated with increased myocarditis (p-value <0.001 and 0.004 respectively). Reduced GLS is associated with higher mechanical ventilation needs (12.17 + 4.79 vs.15.65 + 4.90, p-value 0.02) and a higher mortality rate (11.36 + 4.64 vs. 14.74 + 4.82; p-value 0.005). Increased hs-troponin is associated with higher mechanical ventilation needs (25.33% vs. 3.56%, p-value 0.002) and a higher mortality rate (34.57% vs. 5.76%, p-value 0.002). Compared with contemporary controls, critical COVID-19 patients with myocardial involvement and elevated cardiac troponin level are associated with higher mechanical ventilation needs and a higher mortality rate.
- Open Access
- 15 December 2022
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 64 (6) , 589-594
Association between reversine dose and increased plasticity of dedifferentiated fat (DFAT cells) into cardiac derived cells
C?l: Analyzovat souvislost mezi pod?n?m reversinu a zv??enou plasticitou bun?k DFAT schopn?ch d?len? na r?zn? typy bun?k. Metoda: Vykultivovan? bu?ky DFAT byly rozd?leny do ?ty? skupin podle d?vky reversinu: na kontroln? (bez reversinu) skupin...
- 15 December 2022
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 64 (6) , 589-594
Open AccessAssociation between reversine dose and increased plasticity of dedifferentiated fat (DFAT cells) into cardiac derived cells
C?l: Analyzovat souvislost mezi pod?n?m reversinu a zv??enou plasticitou bun?k DFAT schopn?ch d?len? na r?zn? typy bun?k. Metoda: Vykultivovan? bu?ky DFAT byly rozd?leny do ?ty? skupin podle d?vky reversinu: na kontroln? (bez reversinu) skupin...
- Open Access
- 31 August 2022
- Published by MDPI AG in Preprints.org
Inhibition of Pathological Myofibroblast Differentiation of Valvular Interstitial Cell by Atorvastatin, Olmesartan, and Resveratrol in Experimental Heart Valve Model “Contemporary Model with Rabbit Valve”
Introduction. Recent studies revealed that differentiation of valvular interstitial cell into myofibroblasts played an important role in pathological valve remodeling in rheumatic valvular disease. Objective. To investigate effects of atorvastatin, olmesartan, and resveratrol on Transforming Growth Factor β1-induced fibrosis. Methods. Valvular interstitial cell was isolated from 12-weeks male New Zealand rabbit (Oryctolagus cuniculus). Culture cells was divided into 4 groups, control group, group I (0.5 mg/mL Atorvastatin), group II (100 nmol/L Olmesartan), group III (50 μM/L Resveratrol) and group IV (combinations). All group were exposed to 100 nM Transforming Growth Factor β1 for 24 hours. Results. Immunochemical staining demonstrated that cells were completely differentiated into myofibroblasts with mean expression of α-smooth muscle actin 24522.64±4566.994. Atorvastatin, olmesartan, resveratrol, and its combination significantly reduced α-smooth muscle actin expression (6823±1735.3, 6942.7±2455.9, 14176.2±3343.3, 5051.8±1612.2 respectively (p<0.001). Conclusion. Our data showed atorvastatin, olmesartan, resveratrol, and its combination significantly reduce Transforming Growth Factor β1-induced valvular fibrosis.
- 31 August 2022
- Published by MDPI AG in Preprints.org
Open AccessInhibition of Pathological Myofibroblast Differentiation of Valvular Interstitial Cell by Atorvastatin, Olmesartan, and Resveratrol in Experimental Heart Valve Model “Contemporary Model with Rabbit Valve”
Introduction. Recent studies revealed that differentiation of valvular interstitial cell into myofibroblasts played an important role in pathological valve remodeling in rheumatic valvular disease. Objective. To investigate effects of atorvastatin, olmesartan, and resveratrol on Transforming Growth Factor β1-induced fibrosis. Methods. Valvular interstitial cell was isolated from 12-weeks male New Zealand rabbit (Oryctolagus cuniculus). Culture cells was divided into 4 groups, control group, group I (0.5 mg/mL Atorvastatin), group II (100 nmol/L Olmesartan), group III (50 μM/L Resveratrol) and group IV (combinations). All group were exposed to 100 nM Transforming Growth Factor β1 for 24 hours. Results. Immunochemical staining demonstrated that cells were completely differentiated into myofibroblasts with mean expression of α-smooth muscle actin 24522.64±4566.994. Atorvastatin, olmesartan, resveratrol, and its combination significantly reduced α-smooth muscle actin expression (6823±1735.3, 6942.7±2455.9, 14176.2±3343.3, 5051.8±1612.2 respectively (p<0.001). Conclusion. Our data showed atorvastatin, olmesartan, resveratrol, and its combination significantly reduce Transforming Growth Factor β1-induced valvular fibrosis.